Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Direct tumor cell lysis refers to the process by which immune cells directly kill tumor cells without requiring additional cellular mechanisms. This phenomenon is a critical component of the body's natural defense against cancer and is also leveraged in various immunotherapeutic approaches. It involves mechanisms such as antibody-mediated cytotoxicity, NK cell-mediated lysis, and NKT cell-mediated lysis, all contributing to the direct elimination of tumor cells.
Complement-Dependent Cytotoxicity (CDC), Antibody-Dependent Cellular Cytotoxicity (ADCC), Perforin-Granzyme Pathway, MAPK-Dependent Pathway
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tumor Cell Direct Lysis.